{
  "id": 3632600,
  "title": "Si-Bone chief op & financial officer sells $233,970 in stock",
  "url": "https://urgent.news/2026/08/27/si-bone-chief-op-financial-officer-sells-233-970-in-stock",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-08-27T01:15:59.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/insider-trading-news/sibone-chief-op--financial-officer-sells-233970-in-stock-93CH-4878188"
  },
  "original_language": "en",
  "account": "Anshul Maheshwari, the Chief Operating and Financial Officer of SI-BONE, Inc. (NASDAQ: SIBN), divested 11,636 shares of the company's common stock on August 24, 2026. The transaction spanned a period of time, resulting in a total value of roughly $233,970. The shares were traded at prices varying between $20.00 and $20.25 each, with a weighted average price of $20.1075. The sale was carried out under a pre-established 10b5-1 trading plan, initiated on December 17, 2025. This came after SI-BONE's shares experienced a robust surge, increasing by 25% over the last six months. As of the present, the stock is trading at $19.45, which is marginally under Mr. Maheshwari's selling price. A review by InvestingPro suggests the stock could be overvalued when compared to its Fair Value estimate, placing it on the list of companies deemed most overvalued. For those wanting to delve further, a comprehensive Pro Research Report on SI-BONE is available, among 1,400+ US equities analyzed. Post these transactions, Mr. Maheshwari continues to hold 223,284 shares of SI-BONE common stock, with the remaining balance being the 167,604 shares from the restricted stock units granted to him, each entitling him to one share of the company’s common stock. In other recent developments, SI-BONE disclosed its second-quarter 2026 financial outcomes, surpassing market forecasts. The company reported an adjusted loss of $0.09 per share, a marked improvement over the estimated loss of $0.16 per share. Revenue grew by 15.2% to $56 million, slightly exceeding the expected $55.92 million. Responding to these results, Canaccord Genuity maintained a Buy rating for SI-BONE, setting a price target of $27.00. The firm highlighted the company's robust engagement with U.S. surgeons and increased procedural volumes. Moreover, SI-BONE adjusted its guidance for both revenue and expenses. Despite these favorable developments, the company's stock saw a dip in post-market trading as investors weighed its future prospects and spending intentions.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "Investing.com",
        "title": "Si-Bone CEO Laura Francis sells $522,595 in company stock",
        "url": "https://urgent.news/2026/08/27/si-bone-ceo-laura-francis-sells-522-595-in-company-stock",
        "published": "2026-08-27T01:15:59.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}